Cargando…

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient

We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects. The combination of lenacapavir plus fostemsavir loo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bigirimana, Ferdinand, Van den Wijngaert, Sigi, Fosso, Christelle, Stoffels, Karolien, Martin, Charlotte, Maillart, Evelyne, Clevenbergh, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599868/ https://www.ncbi.nlm.nih.gov/pubmed/37886135 http://dx.doi.org/10.1155/2023/8865265

Ejemplares similares

Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium
por: Mekkaoui, Leila, et al.
Publicado: (2021)

Opportunistic peritonitis in peritoneal dialysis: The example of Paracoccus yeei
por: Fosso, Christelle, et al.
Publicado: (2021)

Fostemsavir for HIV-1 infection
Publicado: (2022)

Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2022)

Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)

Efficacy of systematic coronavirus screening by PCR and viral cultures in addition to triage in limiting the spread of SARS-CoV-2 within a hemodialysis unit
por: Salaouatchi, Mohamed Tayeb, et al.
Publicado: (2021)

Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir
por: Bester, Stephanie M., et al.
Publicado: (2022)

Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection
por: Verhofstede, Chris, et al.
Publicado: (2017)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
por: Swanstrom, Adrienne E., et al.
Publicado: (2023)

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks
por: VanderVeen, Laurie, et al.
Publicado: (2021)

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir
por: Wang, Tao, et al.
Publicado: (2021)

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
por: Cilento, Maria E., et al.
Publicado: (2022)

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir
por: Troyano-Hernáez, Paloma, et al.
Publicado: (2022)

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
por: Gartland, Margaret, et al.
Publicado: (2020)

COVID-19–Associated Fusobacterium nucleatum Bacteremia, Belgium
por: Wolff, Louis, et al.
Publicado: (2021)

GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors
por: Selyutina, Anastasia, et al.
Publicado: (2021)

Streptobacillus moniliformis right hand abscess and monoarthritis following a rat bite
por: Wallemacq, Silvio, et al.
Publicado: (2022)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
por: Sevinsky, Heather, et al.
Publicado: (2017)

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2023)

A zoonotic cause of blood culture-negative infective endocarditis in Belgium: Case report and review of the literature on Q fever
por: Héloïse, Van Noten, et al.
Publicado: (2022)

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
por: Aberg, Judith A., et al.
Publicado: (2023)

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022)

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

Ocular surface manifestations and SARS-CoV-2 RNA detection in conjunctival swabs of patients hospitalized for COVID-19 pneumonia
por: Valyi, Zsuzsanna, et al.
Publicado: (2023)

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
por: Muccini, Camilla, et al.
Publicado: (2022)

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80
por: Kumar, Princy N, et al.
Publicado: (2023)

Invasive non-typhoidal Salmonella infection complicated by metastatic infections: Report of three cases
por: Taliha, Mariana Dumitru, et al.
Publicado: (2022)

Cytomegalovirus haemorrhagic colitis complicating COVID‐19 in an immunocompetent critically ill patient: A case report
por: Leemans, Sophie, et al.
Publicado: (2020)

Dépistage systématique par culture virale des patients COVID en hémodialyse
por: Collart, F., et al.
Publicado: (2020)

547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir
por: Proudfoot, Clare, et al.
Publicado: (2018)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
por: Anderson, Sarah-Jane, et al.
Publicado: (2021)

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
por: Bekerman, Elena, et al.
Publicado: (2023)

1542. Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?
por: Lat, Allen K, et al.
Publicado: (2023)

Conséquences de la pandémie de COVID-19 sur le taux de péritonites de dialyse péritonéale : plaidoyer pour une formation continue ininterrompue
por: Jacobs, Lucas, et al.
Publicado: (2022)

365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
por: Dyson, Alftan, et al.
Publicado: (2023)

1315. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models
por: Nguyen, Dung N, et al.
Publicado: (2020)

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients
por: Moore, Katy P, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1ods989sslv4q32q526t22nbqj